Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRAXD1)

Drug Name	PMID26560530-Compound-7 Drug Info
Cross-matching ID	PubChem CID 6193963 TTD Drug ID DMRAXD1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Tissue transglutaminase (TG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ZED1227	DMDXEN5	Coeliac disease	DA95	Phase 2	[2]
PMID26560530-Compound-13	DMKF26Z	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-54	DM2X4R0	N. A.	N. A.	Patented	[1]
Triazole derivative 1	DM9QB2S	N. A.	N. A.	Patented	[1]
Acyl piperidine derivative 3	DMIDUB4	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-14	DM52MIK	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-1	DMSI7F2	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-3	DM92OT0	N. A.	N. A.	Patented	[1]
PMID26560530-Compound-11	DMZ5UST	N. A.	N. A.	Patented	[1]
Chloroacetyl ester derivative 1	DMW4J0P	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
2	Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells. 2022 May 17;11(10):1667.